Men's multivitamins recalled due to undeclared allergen: FDA

A brand of men's multivitamins has been recalled due to the presence of an undeclared allergen that may prove deadly to some consumers.
The recall pertains to men's multivitamins manufactured by Utah-based company MTN OPS LLC. The recalled Multi-V Men multivitamins come in 60-capsule bottles, and 7,546 bottles are affected in total.
According to the Food and Drug Administration (FDA)'s website, the pills were recalled due to "undeclared soy flour."
The FDA listed the recall as Class II on April 9, which pertains to products that "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
'Extra Creamy' Butter Recalled Due To Stomach-churning Bacterial Contamination
The recalled vitamins have an expiration date of March 2026, and the lot number is #012324177. No other batches of vitamins are included in the recall.
Read On The Fox News App
The multivitamins contain essential vitamins such as calcium, zinc and vitamin C, in addition to vitamin B-12, vitamin D and thiamin.
Click Here To Sign Up For Our Health Newsletter
The pills are intended to support men's "daily health" and "immune health," according to the company's website.
"Men need specific nutrients to maintain optimal health," the product page explains. "Men's Multi-V is a daily multivitamin with essential vitamins and minerals you need to maintain a strong, healthy, and energetic lifestyle."
For more Health articles, visit www.foxnews.com/health.
It is rare, but not unheard of, for over-the-counter pills and multivitamins to be recalled. In 2016, Nature Made announced a recall of some of its vitamins due to fears of possible salmonella or staphylococcus contamination.
In November, some lots of the antianxiety drug clonazepam were recalled after being mislabeled with an incorrect strength and National Drug Code on them.
Fox News Digital reached out to MTN OPS for comment but did not immediately hear back.Original article source: Men's multivitamins recalled due to undeclared allergen: FDA

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

17 minutes ago

• Business Insider

3 simple recipes that make eating fewer ultra-processed foods easy, by a nutritionist

Ultra-processed foods have been linked to health issues such as cardiovascular disease and cancer. While they can be convenient, they should be eaten in moderation, a nutritionist said. Rhiannon Lambert shared recipes for granola, flatbreads, and chocolate peanut bars. In recent years, ultra-processed food has been the subject of endless news reports, books, and online debate. But while research increasingly points to the potential health risks of UPFs, including cardiovascular disease and cancer, they shouldn't necessarily be demonized, the UK-based registered nutritionist Rhiannon Lambert told Business Insider. Processing food can preserve it better, or make it more accessible, she said. "I think UPFs have a place, but they should not be consumed as frequently as they are, and they have become a problem in the sense that most people are now missing out on whole foods by opting for ultra-processed foods instead," Lambert said. In her new book, "The Unprocessed Plate: Simple, Flavourful UPF-free Recipes to Transform Your Life," Lambert explains what people need to know about UPFs and shares recipes to help you eat fewer of them. Below are three recipes that are easy to make from scratch so you can avoid buying ultra-processed versions. Easy yogurt flatbreads "These flatbreads are such a useful recipe to have up your sleeve, and you can use whatever flour you have to hand. Each type of yogurt and flour has different hydration levels, so this recipe is just a guide — if you find the dough is too dry, add splashes of water until it comes together; if you find it's too wet, simply add more flour," Lambert wrote. She continued: "Once you've got the hang of the basic recipe, feel free to experiment by adding some of the optional extras to the dough. The flatbreads are also delicious brushed with a little melted butter as they come out of the pan." Prep: 10 minutes Cook: 10 minutes Nutrition per portion: Fiber: 3.1 grams Protein: 13 grams Ingredients: 400 grams (3 cups/14 ounces) white spelt or wholemeal flour, plus extra to dust 1 tablespoon baking powder 1 teaspoon sea salt 1 teaspoon olive oil, plus extra for frying if needed 200 grams (1 cup/7 ounces) skyr, Greek yogurt, or coconut yogurt Optional extras: Freshly ground black pepper Grated garlic Nigella seeds Cumin seeds Chopped coriander (cilantro) leaves Sliced spring onion (scallion) Desiccated (dried, shredded) coconut Method: 1. Combine the flour, baking powder, and salt in a bowl, then stir in the olive oil and yogurt (add any additional extras now, too). Mix with your hands until the dough comes together, then tip onto a flour-dusted surface and knead for a couple of minutes until you have a smooth dough. Divide the dough into six equal balls, cover with a clean tea (dish) towel, and allow to rest for at least 10 minutes. 2. Meanwhile, set a griddle pan or non-stick frying pan (skillet) over a high heat. 3. Roll each dough ball into a flatbread shape about 20 centimeters (eight inches) long and two millimeters (1⁄8 inch) thick. If your pan isn't non-stick or you want a slightly crisp finish to your flatbreads, brush both sides of the flatbreads with a little olive oil. 4. When the pan is searingly hot, add a flatbread to the pan and cook for 60 to 90 seconds until char marks appear, then flip it over and cook the other side until nicely charred too. Wrap the flatbread in a tea (dish) towel while you cook the rest. Seedy granola "This is such an adaptable recipe that you can make based on what you have in your store cupboard or your personal preferences for flavor and crunch. I love it, as it provides my family and me with lovely healthy fats and fibre for the day ahead. Serve as it is with your preferred milk, or top with fresh fruit and yogurt," Lambert said. Prep: 25 minutes Cook: 40 minutes Nutrition per 40-gram portion: Fiber: 3.3 grams Protein: 5.3 grams Ingredients: 175 grams (6.5 ounces) jumbo oats 175 grams (6.5 ounces) barley, spelt, or rye flakes (or simply use more jumbo oats) 150 grams (5.5 ounces) nuts, roughly chopped (I use a mix of almonds, hazelnuts, pecans, and walnuts) 150 grams (5.5 ounces) seeds (I use a mix of pumpkin, sunflower, sesame, and flaxseeds) 1 tablespoon ground cinnamon, nutmeg, ginger, or cardamom (or a mix) (optional) 50 grams (5 tablespoons/1.75 ounces) coconut oil 100 grams (1⁄3 cup/3.5 ounces) maple syrup 4 tablespoons almond or peanut butter (optional) 75 grams (2.75 ounces) organic* dried fruit, roughly chopped (I use a mix of dried apricots, figs, dates, cranberries, and sour cherries) Sea salt *Select organic dried fruit to ensure it doesn't contain additives like sulphur dioxide Method: 1. Preheat the oven to 160°C/140°C fan/325°F and line your largest baking sheet with baking paper. 2. Mix all the dry ingredients in a large bowl. 3. Melt the coconut oil in a small saucepan over a low heat (or melt in the microwave for 30 seconds). Stir in the maple syrup, nut butter (if using), and a pinch of salt, then mix until fully combined. Pour over the dry ingredients and stir until everything is nicely coated. 4. Spread out in an even layer on the baking sheet and bake for 30 to 35 minutes until golden, stirring and tossing occasionally so that it cooks evenly. 5. Leave to cool on the tray, then stir in the dried fruit. 6. Store in an airtight container at room temperature for up to one week. Note: You can cook this using your air fryer too. Heat the air fryer to 160°C/325°F and air fry for 10 to 12 minutes, tossing occasionally. You may need to air fry the granola in two batches depending on the size of your air fryer, for ultimate crispness. It will crisp up further as it cools. Chocolate, peanut, and date bars "Sticky, nutty, and chocolatey, these are the ultimate pick-me-up. You can slice these into smaller bars if you like, but be aware that you may need a little more chocolate to coat all of them. In the summer, I love to eat these straight out of the freezer sprinkled with a tiny pinch of flaky salt," Lambert said. Makes about 15 bars Cook: five minutes Nutrition per bar: Fibre: 3.3 grams Protein: 5 grams Ingredients: 75 grams (3⁄4 cup/2.75 ounces) jumbo or rolled oats 300 grams (10.5 ounces) pitted Medjool dates 4 tablespoons smooth peanut butter 1.5 teaspoons vanilla extract 0.25 teaspoon sea salt 80 grams (2.75 ounces) unsalted roasted peanuts 175 grams (6.25 ounces) dark (bittersweet) chocolate (at least 75% cocoa solids), broken into small pieces 2 teaspoons coconut oil 1. Line a 20-centimeter (8-inch) square cake pan with baking paper, with plenty of overhang. Place the oats in a blender or food processor and blitz to a fine flour, then tip into a bowl and set aside. 2. Place the dates in the blender or food processor (no need to clean it) with the peanut butter, vanilla, and salt. Roughly blitz, then slowly add 75 milliliters (five tablespoons/2.5 fluid ounces) of water until you have a smooth, thick paste. Be sure to scrape down the sides occasionally. Remove 300 grams (10.5 ounces) of the date mix to a bowl and set aside. 3. Add the oat flour back to the blender or food processor with the remaining date mix and pulse a few times until it's nicely combined. Tip the mixture into the base of the lined pan and use wet fingertips to spread it into a smooth layer that fills the tin. 4. Spread the remaining date mixture on top, smoothing it with a spatula. Evenly sprinkle over the nuts, pushing them in a little. Place in the freezer for at least six hours or ideally overnight until frozen and firm. 5. Lift the frozen slab out of the pan and slice into 15 bars. Line a baking sheet with baking paper. 6. Add the chocolate and coconut oil to a heatproof bowl set over a pan of barely simmering water and heat until just melted, stirring to combine. Alternatively, heat in a microwave on the lowest setting in 30-second blasts, stirring between each, until just melted. If you have a cooking thermometer, the chocolate is ready when it reads 45 to 50°C (113 to 122°F). 7. Working one at a time, submerge the bars in the melted chocolate, using two forks to turn them. Lift out of the bowl using the forks, allowing the excess chocolate to drip back into the bowl, then transfer them to the lined sheet. Once all the bars are coated in chocolate, return the sheet to the freezer or fridge for at least 15 minutes until the chocolate is set. Store in an airtight container in the fridge for up to two weeks or freezer for up to four weeks, but I assure you they won't last long! Note: If you can't find roasted peanuts, simply use unroasted peanuts and roast them in the oven at 180°/160°fan/350°F for eight to 12 minutes until golden. Then use in the recipe as specified.

Associated Press

18 minutes ago

• Associated Press

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous. ITM-91/ITM-94 is a first-in-class, peptide-based theranostic pair combining the radiotherapeutic compound ITM-91 (Debio 0228) ([177Lu]Lu-DPI-4452), with the diagnostic agent ITM-94 (Debio 0328) ([68Ga]Ga-DPI-4452) to target Carbonic Anhydrase IX (CAIX). CAIX is a cell surface protein that plays a key role in the tumor microenvironment, promoting tumor growth, survival, invasion and metastasis. In September 2024, ITM gained the exclusive worldwide license from Debiopharm for the development and commercial rights of ITM-91/ITM-94. The initiation of this study arm represents a significant advancement for ITM and Debiopharm following their licensing agreement. In the now initiated Part D of the trial, ITM-94 is being evaluated for its effectiveness to accurately classify an indeterminate renal mass as ccRCC or non-cancerous, when compared to CT/MRI imaging and histopathology. Secondary endpoints include sensitivity, specificity, and the positive and predictive value of ITM-94 PET/CT imaging compared to histopathology. This study arm is expected to enroll approximately 36 patients at around 15 clinical sites across the EU, US and Australia. ' The early results from the Gallium-68 CAIX PET/CT diagnostic are remarkable to date. I believe ITM-94 has the potential to change the way urologists and oncologists diagnose and stage patients with clear cell renal cell carcinoma, improving accuracy and reducing the need for biopsies. I have not seen a tracer with a similar profile since the PSMA PET/CT was established,' added Prof. Michael Hofman, Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Peter MacCallum Cancer Centre, Melbourne, Australia. ' Clear cell renal cell carcinoma is the most common form of kidney cancer, with more than 90% of cases overexpressing the CAIX encoding gene. As survival rates are highly dependent on the stage of progression, rapid and precise diagnosis is essential to provide patients with the best possible treatment options and therapeutic outcomes. ITM-94 has already demonstrated potential exceptional imaging qualities, including high tumor-to-background ratios and detecting lesions not visible by CT scan with a potential favorable safety profile. We look forward to exploring the full potential of the theranostic pair ITM-91/ITM-94 across this trial to characterize and treat CAIX expressing cancer cells, advancing the efficacy of targeted radiopharmaceutical therapies,' said Dr. Celine Wilke, Chief Medical Officer of ITM. ' With high-quality imaging and high tumor uptake, ITM-94 has already demonstrated potentially significant diagnostic capabilities in solid tumors. The data gathered in Part D of the trial will be instrumental to the further validation of this theranostic pair. We highly value our partnership with ITM, which will continue to advance the rapid progression of these novel radio-diagnostics and -therapeutics through the clinic,' said Angela Zubel, Chief Development Officer, Research & Development at Debiopharm. About the Phase 1/2 ITM-91/ITM-94 Trial The five-part clinical trial (NCT05706129) is designed to assess the safety and tolerability, imaging characteristics, and efficacy of the theranostic pair ITM-91/ITM-94 in patients with unresectable, locally advanced or metastatic solid tumors. In Part A of the trial, ITM-94 demonstrated exceptional tumor imaging characteristics, with a high tumor-to-background ratio and a favorable tolerability profile in patients with confirmed ccRCC, with results published in the Journal of Nuclear Medicine. Part B, which is ongoing, is assessing escalating doses of the therapeutic agent, ITM-91, in patients whose tumors show high uptake of the imaging tracer. Based on the recommended dose from Part B, Part C of the trial will assess the safety and preliminary efficacy of ITM-91 in patients with ccRCC, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma and potentially other tumor types. In addition to the newly initiated Part D, Part E will assess ITM-94 uptake in other tumors. ITM will assume full sponsorship of the program from Debiopharm once the transfer is completed. About ITM-91/ITM-94 (Debio 0228/ 0328) ITM-91/ITM-94 is an investigational theranostic pair originally discovered by 3B Pharmaceuticals GmbH and now exclusively licensed to ITM. ITM-94 ([68Ga]Ga-DPI-4452) is a PET imaging agent that may be used independently and is designed to identify patients whose cancers overexpress CAIX. Once identified, these patients may be treated with the lutetium-labelled radioligand, ITM-91 ([177Lu]Lu-DPI-4452), which delivers targeted radiation to the tumor with the aim to destroy it from the inside. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit We are on X. Follow us @DebiopharmNews at or on LinkedIn. ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: [email protected] Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: [email protected] Debiopharm Contact Dawn Bonine - Head of Communications [email protected] Tel: +41 (0)21 321 01 11 Attachment

Fox News

34 minutes ago

• Fox News

President Trump Drops The 'Hammer' On Iran

On Saturday night, the U.S. military attacked several Iranian nuclear facilities in an attempt to eliminate their potential. Following the announcement, President Trump addressed the nation, boasting the U.S. 'obliterated' Iran's nuclear capabilities. Some Americans fear this may drag the United States into an open-ended war. However, the Trump administration rejects those claims. Chairman of the House Intelligence Committee, Rep. Rick Crawford (AR-01) joins the Rundown to discuss what inspired the President to act in a swift, secretive manner while enabling the U.S. military to strike the Iranian nuclear facilities. He shares his hope that the strike will embolden the Iranian people to rise against their repressive regime. President Donald Trump is taking a closer look at infant formula, a topic that the Food and Drug Administration (FDA) hasn't thoroughly examined in decades. The last comprehensive review of infant formula was conducted in 1998, over two decades ago. Currently, a new FDA panel is seeking answers regarding childhood diseases, such as obesity and diabetes. Former FDA Commissioner Dr. David Kessler, the author of 'Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight,' joins to discuss strategies for improving health, the popularity of Ozempic-like drugs, and whether or not food companies are trying to get us addicted to junk food. Plus, commentary from senior policy analyst at the Competitive Enterprise Institute, Ben Lieberman. Photo Credit: AP Learn more about your ad choices. Visit